Loading...
•
Sep 30, 2024
Maravai Q3 2024 Earnings Report
Reported third quarter results with revenue of $65.2 million and announced agreement to acquire the DNA and RNA business of Officinae Bio.
Key Takeaways
Maravai LifeSciences reported a 2.5% decrease in revenue for the third quarter, totaling $65.2 million. The company experienced a net loss of $(176.0) million, which included a goodwill impairment of $154.2 million. They updated their full-year revenue guidance for 2024 to a range of $255.0 million to $265.0 million.
Quarterly revenue reached $65.2 million.
Net loss was $(176.0) million, including a goodwill impairment of $154.2 million.
Adjusted EBITDA was $12.7 million.
Full year 2024 revenue guidance updated to $255.0 million to $265.0 million.
Revenue by Segment
Forward Guidance
Revenue expectations for 2024 are now expected to be in the range of $255.0 million to $265.0 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 16% to 18%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...